[go: up one dir, main page]

MX2022001266A - Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. - Google Patents

Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Info

Publication number
MX2022001266A
MX2022001266A MX2022001266A MX2022001266A MX2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A MX 2022001266 A MX2022001266 A MX 2022001266A
Authority
MX
Mexico
Prior art keywords
hbv
treatment
induced diseases
infection
dihydropyrimidine derivatives
Prior art date
Application number
MX2022001266A
Other languages
English (en)
Inventor
Zhanling Cheng
Zhiguo Liu
Yimin Jiang
Linglong Kong
Jianping Wu
Yanping Xu
Gang Deng
Chao Liang
Xiangjun Deng
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2022001266A publication Critical patent/MX2022001266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se proporcionan derivados de dihidropirimidina que son útiles en el tratamiento o la prevención de la infección por VHB o de enfermedades inducidas por VHB, más particularmente de la infección crónica por VHB o de enfermedades inducidas por la infección crónica por VHB, así como también aplicaciones farmacéuticas o médicas de estos.
MX2022001266A 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. MX2022001266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019098571 2019-07-31
PCT/CN2020/105765 WO2021018238A1 (en) 2019-07-31 2020-07-30 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
MX2022001266A true MX2022001266A (es) 2022-05-03

Family

ID=74228605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001266A MX2022001266A (es) 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Country Status (10)

Country Link
US (1) US20220281865A1 (es)
EP (1) EP4003997A4 (es)
JP (1) JP2022543010A (es)
KR (1) KR20220041853A (es)
CN (1) CN114174300A (es)
AU (1) AU2020322598A1 (es)
BR (1) BR112022001564A2 (es)
CA (1) CA3146997A1 (es)
MX (1) MX2022001266A (es)
WO (1) WO2021018238A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022257942A1 (en) * 2021-06-09 2022-12-15 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
EP2892893B2 (en) * 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JP6533217B2 (ja) * 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
JP6306750B2 (ja) * 2014-03-07 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための新規な６−縮合ヘテロアリールジヒドロピリミジン
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2017064156A1 (en) * 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Also Published As

Publication number Publication date
BR112022001564A2 (pt) 2022-07-12
EP4003997A1 (en) 2022-06-01
EP4003997A4 (en) 2023-08-02
JP2022543010A (ja) 2022-10-07
CN114174300A (zh) 2022-03-11
US20220281865A1 (en) 2022-09-08
KR20220041853A (ko) 2022-04-01
AU2020322598A1 (en) 2022-03-24
WO2021018238A1 (en) 2021-02-04
CA3146997A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3790866A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018011095A (es) Compuestos de carbapenem.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c